Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Press center
  3. Press releases
  4. Siemens Healthineers: Imaging and Precision Therapy on track, Diagnostics faces challenging environment; outlook updated
New corporate headquarters in Erlangen
Press release

Siemens Healthineers: Imaging and Precision Therapy on track, Diagnostics faces challenging environment; outlook updated

Siemens Healthineers AG today announces its results for the second quarter of fiscal year 2026 ended March 31, 2026.
Published on May 7, 2026

Q2 Fiscal Year 2026

  • Equipment book-to-bill ratio of 1.02
  • Imaging comparable revenue growth of 6.1%; adjusted EBIT margin of 22.4%
  • Precision Therapy comparable revenue growth of 4.7%; adjusted EBIT margin of 13.3%
  • Diagnostics comparable revenue decline of 6.5% mainly due to a structural change in the China market environment; adjusted EBIT margin of 0.9%
  • Overall comparable revenue growth of 3.1%
  • Adjusted EBIT margin of 14.7%, impacted by tariffs and currency effects
  • Adjusted basic earnings per share of €0.53, almost at prior-year level
  • Free cash flow of €389 million

Updated Outlook for Fiscal Year 2026

As a result of the structural change in the Chinese Diagnostics market and more pronounced inflation assumptions during the quarter, we update our outlook for fiscal year 2026. For fiscal year 2026, we now expect comparable revenue growth of between 4.5% and 5.0% over fiscal year 2025 (previously between 5% to 6%). For adjusted basic earnings per share, we now expect a range of between €2.20 and €2.30 (previously between €2.20 and €2.40).

Bernd Montag, CEO of Siemens Healthineers AG:

”While the environment remains tough, our synergetic core of Imaging and Precision Therapy is on track with good momentum. We are also taking measures for the future of the company by initiating the next steps to create options for Diagnostics and introducing an evolution of the leadership team.“

Download Quarterly Statement(pdf, 266.87 KB)

Siemens Healthineers 2026

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at siemens-healthineers.com.